The global Peptide Synthesis market size was USD 4.3 Billion in 2021 and is projected to reach USD 6.2 Billion by 2030, exhibiting a CAGR of 7.7% during the forecast period. Peptide molecules have acquired a lot of traction in the healthcare and nutrition industries, and there have been various technological breakthroughs to help in peptide manufacture and synthesis. This pattern has been seen in both enzymatic and chemical peptide production. The usage of peptides in the pharmaceutical and consumer healthcare industries is driving the market's expansion. Peptides offer a wide range of uses in the treatment of malignancies, diabetes, and obesity, among other lifestyle problems. The rising prevalence of these metabolic and lifestyle diseases is opening the path for peptide therapies to be used in oncology and metabolic illnesses. According to a survey published by the International Diabetes Federation in 2020, around 463 million individuals have diabetes in 2019, with the prevalence expected to reach 700 million by 2045. Kind 2 diabetes is the most common type of diabetes, accounting for over 90% of all diabetes cases worldwide.
 

The increasing usage of peptides in pharmaceutical treatments, increased research activities and funding for R&D, and the development of improved automated peptide synthesizers are all driving this market forward. During the projection period, however, the lack of a consistent set of rules for therapeutic peptides and the high cost of instruments are projected to limit market growth.
 

The outbreak of COVID-19 impacted positively on the growth of the global peptide synthesis market. Peptides are rapidly being developed and repurposed in the search for COVID-19 therapies. Chemically synthesised polypeptides bigger than 40 amino acids but less than 100 amino acids in size (synthetic proteins) and synthetic peptides 40 amino acids or less were included to the FDA's definition of biologics in February 2020. According to Clinical Trials.gov, 21 peptide drugs were in development for the treatment of COVID-19 in May 2020, including 15 synthetic peptides for acute respiratory distress syndrome (ARDS), a life-threatening condition in which the lungs are unable to provide enough oxygen to the body's vital organs, and other respiratory illnesses caused by SARS-Cov-2 infection.
 

Product Outlook

The reagents segment is expected to dominate the market share in 2020 of global peptide synthesis market owing to the growing use of peptides in therapeutics, drug design, and gene synthesis, as well as the frequent purchase of reagents over equipment, the growing number of ongoing research projects involving peptide synthesis, and the availability of various peptide synthesis reagents on the market, all contribute to this segment's large share.
 

Technology Outlook

The liquid phase peptide synthesis segment is expected to dominate the market share in 2020 of global peptide synthesis market due to peptide synthesis costs have been reduced significantly thanks to technological advancements and the integration of automation in liquid phase peptide synthesis. This is predicted to boost peptide synthesis adoption around the world, contributing to the worldwide revenue generated over the forecast period. According to conventional research, SPPS is a good approach for GMP manufacturing and API process development since it is cost-effective to synthesis lengthy peptide sequences (more than 10 amino acids) with smaller volumes.
 

Application Outlook

The therapeutics segment is expected to dominate the market share in 2020 of global peptide synthesis market due to increasing metabolic diseases including infectious diseases, pain, dermatology, CNS, renal, and others. Because to a solid pipeline and a large number of peptide candidates for type 2 diabetes treatment. Newly identified peptides that play a key role in metabolic control are expected to aid in the development of successful treatment approaches.
 

End-user Outlook

The pharmaceutical & biotechnology companies segment is expected to dominate the market share in 2020 of global peptide synthesis market due to peptide therapies are becoming more popular as they are more cost-effective, efficient, and have lesser toxicity. These peptides are now being used extensively in COVID-19 research. Relief Therapeutics, based in Switzerland, is evaluating the effect of Aviptadil, a patented synthetic form of a human vasoactive intestinal polypeptide (VIP), for COVID-19-related ARDS at New York University Langone (NYU Langone Health), as part of the FDA's Coronavirus Treatment Acceleration Program (CTAP). Various pharmaceutical and biotechnology businesses are developing new oral medications, which is projected to raise demand for this segment.
 

Regional Outlook

North America is expected to dominate the market share in 2020 of global peptide synthesis market. The regional market has benefited by increased investments in the development of structure-based medication designs, significant research in the domains of genomes and proteomics, and a growing focus on producing individualized treatments. In 2020, the United States had the largest share of the North American market. The United States' substantial share is primarily due to the country's growing life science research efforts and the rising prevalence of cancer and chronic disorders.
 

Key Companies & Recent Developments

Partnerships, strategic mergers, and acquisitions are expected to be the most successful strategies for industry participants to get speedy access to growing markets while also improving technological capabilities. In addition, product differentiation and developments, as well as service expansion, are projected to help organizations thrive in the market. For instance, in November 2019, AstraZeneca announced initiatives in China to improve global research and development (R&D) for innovative medicines and peptide therapies. In May 2019, CEM Corporation launched Liberty PRO, the automated microwave peptide synthesizer.
 

Market Segmentation of Global Peptide Synthesis Market

By Product

• Reagents
• Equipment
• Services

By Technology

• Solid Phase Peptide Synthesis (SPPS)
• Liquid Phase Peptide Synthesis (LPPS)
• Hybrid Technology

By Application

• Therapeutics
• Diagnosis
• Research

By End User

• Pharmaceutical & Biotechnology Companies
• Contract Development & Manufacturing Organization/Contract Research Organization
• Academic & Research Institutes

Key Players

• Genscript Biotech
• Bachem Holding AG
• Merck KGaA
• Kaneka Corporation
• Bachem Holdings
• Biotage
• CEM Corporation
• Thermo Fisher
• ProteoGenix
• Creative Diagnostics
• Polypeptide Group
• Syngene International Ltd.
• PuroSynth
• Lonza
• MP Biomedicals
• Novo Nordisk A/S